Consort Medical (LON:CSRT) subsidiary Bespak said today that it inked a development agreement with an undisclosed biopharmaceutical company for its Syrina auto-injector.
The deal makes Bespak responsible for early-stage development of the auto-injector. If the undisclosed partner agrees to commercialize the developed product, both parties will enter into a full commercial supply agreement, the company said.
Rather than using a spring to drive the delivery of a drug, Syrina uses a liquid gas propellant. This alternative technique can deliver a broader range of drug formulations and volumes, while reducing potential for glass syringe breakage, the company reported.
“We are delighted to initiate this collaboration for the development of a Syrina auto-injector product,” CEO Jonathan Glenn said in prepared remarks. “This reinforces Bespak’s position as a leading provider of drug-delivery device solutions. We believe that Syrina and Vapoursoft offer significant opportunities for pharmaceutical and biopharmaceutical companies to develop patient-centric presentations of their drugs.”
In September, AstraZeneca (NYSE:AZN) inked a multi-year commercial supply deal with Bespak for its pressurized metered-dose inhaler technology.
The AstraZeneca deal for Bespak came just months after the FDA delayed its decision date for Consort’s generic Advair inhaler to March 2017, which distracted analysts from their impressive finish in fiscal 2016.
